drugset
drugset / Trial / NCT04089267

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

NCT04089267 ↗

Phase 4 Completed 288 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).

Timeline

Start
2016-12
Primary completion
2018-12
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 7500 iu Other
Subject recombinant human thrombopoietin Protein / enzyme biologic 15000 iu Other
Subject recombinant human thrombopoietin Protein / enzyme biologic 30000 iu Other

Indications

autoimmune thrombocytopenic purpura